Abstract
Antimalarial drug discovery has historically benefited from the whole-cell (phenotypic) screening approach to identify lead molecules in the search for new drugs. However over the past two decades there has been a shift in the pharmaceutical industry to move away from whole-cell screening to target-based approaches. As part of a Wellcome Trust and Medicines for Malaria Venture (MMV) funded consortium to discover new blood-stage antimalarials, we used both approaches to identify new antimalarial chemotypes, two of which have progressed beyond the lead optimization phase and display excellent in vivo efficacy in mice. These two advanced series were identified through a cell-based optimization devoid of target information and in this review we summarize the advantages of this approach versus a target-based optimization. Although the each lead optimization required slightly different medicinal chemistry strategies, we observed some common issues across the different the scaffolds which could be applied to other cell based lead optimization programs.
Keywords: Lead-optimization, malaria, whole-cell screening, spiroindolones, imidazolopiperazines, lead optimization phase, in vivo efficacy, scaffolds, dihydrofolate reductase inhibition (DHFR), HTS (high-throughput screen)
Current Topics in Medicinal Chemistry
Title: Back to the Future: Lessons Learned in Modern Target-based and Whole-Cell Lead Optimization of Antimalarials
Volume: 12 Issue: 5
Author(s): Arnab K. Chatterjee and Bryan K.S. Yeung
Affiliation:
Keywords: Lead-optimization, malaria, whole-cell screening, spiroindolones, imidazolopiperazines, lead optimization phase, in vivo efficacy, scaffolds, dihydrofolate reductase inhibition (DHFR), HTS (high-throughput screen)
Abstract: Antimalarial drug discovery has historically benefited from the whole-cell (phenotypic) screening approach to identify lead molecules in the search for new drugs. However over the past two decades there has been a shift in the pharmaceutical industry to move away from whole-cell screening to target-based approaches. As part of a Wellcome Trust and Medicines for Malaria Venture (MMV) funded consortium to discover new blood-stage antimalarials, we used both approaches to identify new antimalarial chemotypes, two of which have progressed beyond the lead optimization phase and display excellent in vivo efficacy in mice. These two advanced series were identified through a cell-based optimization devoid of target information and in this review we summarize the advantages of this approach versus a target-based optimization. Although the each lead optimization required slightly different medicinal chemistry strategies, we observed some common issues across the different the scaffolds which could be applied to other cell based lead optimization programs.
Export Options
About this article
Cite this article as:
K. Chatterjee Arnab and K.S. Yeung Bryan, Back to the Future: Lessons Learned in Modern Target-based and Whole-Cell Lead Optimization of Antimalarials, Current Topics in Medicinal Chemistry 2012; 12 (5) . https://dx.doi.org/10.2174/156802612799362977
DOI https://dx.doi.org/10.2174/156802612799362977 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Structure Guided Design of Biotin Protein Ligase Inhibitors for Antibiotic Discovery
Current Topics in Medicinal Chemistry State-of-the-Art and Projected Developments of Nanofiber Filter Material for Face Mask Against COVID-19
Recent Patents on Nanotechnology Small-Molecule Modulators of the NF-κB Pathway Newly Identified by a Translocation-Based Cellular Assay
Current Topics in Medicinal Chemistry The Concept of Repurposing in COVID-19 Infection
Coronaviruses ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry World’s First Experience of the Low-Dose Radionuclide Inhalation Therapy in the Treatment of COVID-19-Associated Viral Pneumonia: Phase 1/2 Clinical Trial
Current Radiopharmaceuticals Fragment-Based Discovery of Inhibitors of Protein Kinase B
Current Topics in Medicinal Chemistry Liver and COVID-19 - A Review and Clinical Approach
Coronaviruses Meet Our Editor-in-Chief
Letters in Drug Design & Discovery Epidemiological Study of COVID-19 in Iran and the World: A Review Study
Infectious Disorders - Drug Targets (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry One-pot Synthesis of Pyrano[2,3-c]pyrazole Derivatives <i>via</i> Multicomponent Reactions (MCRs) and their Applications in Medicinal Chemistry
Mini-Reviews in Organic Chemistry Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Cytotoxic Evaluation, and Molecular Docking Studies of New Oxadiazole Analogues
Letters in Organic Chemistry Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Medicinal Importance, Pharmacological Activities and Analytical Aspects of a Flavonoid Glycoside ‘Nicotiflorin’ in the Medicine
Drug Metabolism and Bioanalysis Letters TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Photocatalysis and Virus. From Theory to Applications
Journal of Photocatalysis